Study #2024-1502
A phase 1b/2a, randomized, double-blind study to investigate safety, tolerability, PK, PD, and preliminary efficacy of oral administration of SNIPR001 in patients with hematologic malignancy scheduled for allogeneic hematopoietic stem-cell transplantation receiving fluoroquinolone prophylaxis and harboring fluoroquinolone-resistant Escherichia coli pre-transplant
MD Anderson Study Status
Enrolling
Treatment Agent
Description
Phase 1b/2a study to investigate safety and efficacy of oral administration of SNIPR001
Resources and Links
Phone Number: 1-877-MDA-6789
clinicaltrials.gov NCT No: N/A
Information and next steps
Disease:
Unknown Sites
Study phase:
Phase I/II
Physician name:
George Chen
Department:
Stem Cell Transplantation
For general questions about clinical trials:
1-866-499-8634
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.